Targeting key proximal drivers of type 2 inflammation in disease

Nature Reviews Drug Discovery

Volumn 15, Issue 1, 2016, Pages 35-50

  Gandhi, Namita A ^a   Bennett, Brandy L ^a   Graham, Neil M H ^a   Pirozzi, Gianluca ^b   Stahl, Neil ^a   Yancopoulos, George D ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRAKINCEPT; AMG 317; ANRUKINZUMAB; ANTIASTHMATIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; DUPILUMAB; GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 25; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; LEBRIKIZUMAB; LIDOCAINE; MEPOLIZUMAB; METHOTREXATE; MYCOPHENOLATE MOFETIL; OMALIZUMAB; PITRAKINRA; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; MONOCLONAL ANTIBODY;

ALLERGIC DISEASE; ASTHMA; ATOPIC DERMATITIS; CELL DIFFERENTIATION; CHRONIC SINUSITIS; CLINICAL EFFECTIVENESS; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; ENDOCRINE DISEASE; EOSINOPHILIA; EPISTAXIS; FLUID RETENTION; GASTROINTESTINAL DISEASE; GLUCOSE INTOLERANCE; HEADACHE; HUMAN; HYPERTENSION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; INJECTION SITE REACTION; MUSCLE WEAKNESS; NONHUMAN; NOSE POLYP; OROPHARYNX PAIN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; PROTEIN TRANSPORT; PRURITUS; REVIEW; RHINOPHARYNGITIS; SKIN INFECTION; SYMPTOMATOLOGY; TH1 CELL; TH2 CELL; TREATMENT DURATION; TREATMENT RESPONSE; URTICARIA; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DRUG EFFECTS; HELPER CELL; IMMUNOLOGY; INFLAMMATION; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANTIBODIES, MONOCLONAL; HUMANS; INFLAMMATION; INTERLEUKIN-13; INTERLEUKIN-4; INTERLEUKIN-5; MODELS, IMMUNOLOGICAL; MOLECULAR TARGETED THERAPY; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84955179781     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4624     Document Type: Review

References (149)

1. Asher, M. I. et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 368, 733-743 (2006).
2. Pawankar, R., Canonica, G., Holgate, S. & Lockey, R. WAO White Book on Allergy 2011-2012: Executive Summary (World Allergy Organization, 2011).
3. Prescott, S. L. et al. A global survey of changing patterns of food allergy burden in children. World Allergy Organ. J. 6, 21 (2013).
4. Kay, A. B. Allergy and allergic diseases. Second of two parts. N. Engl. J. Med. 344, 109-113 (2001).
5. Kay, A. B. Allergy and allergic diseases. First of two parts. N. Engl. J. Med. 344, 30-37 (2001).
6. Wynn, T. A. Type 2 cytokines: mechanisms and therapeutic strategies. Nat. Rev. Immunol. 15, 271-282 (2015).
7. Peebles, R. S. Jr. At the bedside: the emergence of group 2 innate lymphoid cells in human disease. J. Leukoc. Biol. 97, 469-475 (2015).
8. Leung, D. Y. & Bieber, T. Atopic dermatitis. Lancet 361, 151-160 (2003).
9. Adcock, I. M., Maneechotesuwan, K. & Usmani, O. Molecular interactions between glucocorticoids and long-acting β2 agonists. J. Allergy Clin. Immunol. 110, S261-S268 (2002).
10. Haeck, I. M. et al. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J. Am. Acad. Dermatol. 64, 1074-1084 (2011).
11. Seale, J. P. & Compton, M. R. Side-effects of corticosteroid agents. Med. J. Aust. 144, 139-142 (1986).
12. Nesbitt, L. T. Jr. Minimizing complications from systemic glucocorticosteroid use. Dermatol. Clin. 13, 925-939 (1995).
13. Jacobi, A., Antoni, C., Manger, B., Schuler, G. & Hertl, M. Infliximab in the treatment of moderate to severe atopic dermatitis. J. Am. Acad. Dermatol. 52, 522-526 (2005).
14. Fahy, J. V. et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am. J. Respir. Crit. Care Med. 155, 1828-1834 (1997).
15. Busse, W. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108, 184-190 (2001).
16. Soler, M. et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 18, 254-261 (2001).
17. Gevaert, P. et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J. Allergy Clin. Immunol. 131, 110-116. e1 (2013).
18. Maurer, M., Rosen, K. & Hsieh, H. J. Omalizumab for chronic urticaria. N. Engl. J. Med. 368, 2530 (2013).
19. Saini, S. S. et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J. Invest. Dermatol. 135, 925 (2015).
20. Zuberbier, T. & Maurer, M. Omalizumab for the treatment of chronic urticaria. Expert Rev. Clin. Immunol. 11, 171-180 (2015).
21. Heil, P. M., Maurer, D., Klein, B., Hultsch, T. & Stingl, G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course-a randomized, placebo-controlled and double blind pilot study. J. Dtsch. Dermatol. Ges. 8, 990-998 (2010).
22. Jeong, C. W. et al. Differential in vivo cytokine mRNA expression in lesional skin of intrinsic versus extrinsic atopic dermatitis patients using semiquantitative RT PCR. Clin. Exp. Allergy 33, 1717-1724 (2003).
23. Suαrez-Fari?as, M. et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J. Allergy Clin. Immunol. 132, 361-370 (2013).
24. Akdis, C. A. & Akdis, M. Immunological differences between intrinsic and extrinsic types of atopic dermatitis. Clin. Exp. Allergy 33, 1618-1621 (2003).
25. Ying, S. et al. Expression of IL 4 and IL 5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J. Immunol. 158, 3539-3544 (1997).
26. Green, R. H. et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360, 1715-1721 (2002).
27. Bentley, A. M. et al. Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma. Relationship to symptoms and bronchial responsiveness. Am. Rev. Respir. Dis. 146, 500-506 (1992).
28. Gittler, J. K. et al. Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J. Allergy Clin. Immunol. 130, 1344-1354 (2012).
29. Hamid, Q., Boguniewicz, M. & Leung, D. Y. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J. Clin. Invest. 94, 870-876 (1994).
30. Grewe, M. et al. Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients. J. Invest. Dermatol. 105, 407-410 (1995).
31. Pacor, M. L. et al. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clin. Exp. Allergy 34, 639-645 (2004).
32. Suárez-Farias, M. et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J. Allergy Clin. Immunol. 127, 954-964. e4 (2011).
33. Kakinuma, T. et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J. Allergy Clin. Immunol. 107, 535-541 (2001).
34. Hijnen, D. et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J. Allergy Clin. Immunol. 113, 334-340 (2004).
35. Jahnz-Rozyk, K., Targowski, T., Paluchowska, E., Owczarek, W. & Kucharczyk, A. Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis. Allergy 60, 685-688 (2005).
36. Imai, T. et al. The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J. Biol. Chem. 272, 15036-15042 (1997).
37. van Drunen, C. M., Reinartz, S., Wigman, J. & Fokkens, W. J. Inflammation in chronic rhinosinusitis and nasal polyposis. Immunol. Allergy Clin. North Am. 29, 621-629 (2009).
38. Meltzer, E. O. et al. Rhinosinusitis: establishing definitions for clinical research and patient care. J. Allergy Clin. Immunol. 114, 155-212 (2004).
39. Van Zele, T. et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 61, 1280-1289 (2006).
40. Van Cauwenberge, P., Van Hoecke, H. & Bachert, C. Pathogenesis of chronic rhinosinusitis. Curr. Allergy Asthma Rep. 6, 487-494 (2006).
41. Aouad, R. K. & Chiu, A. G. State of the art treatment of nasal polyposis. Am. J. Rhinol. Allergy 25, 291-298 (2011).
42. Noben-Trauth, N. et al. An interleukin 4 (IL 4)- independent pathway for CD4+ T cell IL 4 production is revealed in IL 4 receptor-deficient mice. Proc. Natl Acad. Sci. USA 94, 10838-10843 (1997).
43. Kopf, M. et al. Disruption of the murine IL 4 gene blocks TH2 cytokine responses. Nature 362, 245-248 (1993).
44. Barner, M., Mohrs, M., Brombacher, F. & Kopf, M. Differences between IL 4Rα deficient and IL 4 deficient mice reveal a role for IL 13 in the regulation of Th2 responses. Curr. Biol. 8, 669-672 (1998).
45. Liddiard, K. et al. Interleukin 4 induction of the CC chemokine TARC (CCL17) in murine macrophages is mediated by multiple STAT6 sites in the TARC gene promoter. BMC Mol. Biol. 7, 45 (2006).
46. Wirnsberger, G., Hebenstreit, D., Posselt, G., Horejs-Hoeck, J. & Duschl, A. IL 4 induces expression of TARC/CCL17 via two STAT6 binding sites. Eur. J. Immunol. 36, 1882-1891 (2006).
47. Mochizuki, M., Bartels, J., Mallet, A. I., Christophers, E. & Schroder, J. M. IL 4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy. J. Immunol. 160, 60-68 (1998).
48. Hoeck, J. & Woisetschlager, M. STAT6 mediates eotaxin 1 expression in IL 4 or TNF-α-induced fibroblasts. J. Immunol. 166, 4507-4515 (2001).
49. Swain, S. L., Weinberg, A. D., English, M. & Huston, G. IL 4 directs the development of Th2 like helper effectors. J. Immunol. 145, 3796-3806 (1990).
50. Lazarski, C. A., Ford, J., Katzman, S. D., Rosenberg, A. F. & Fowell, D. J. IL 4 attenuates Th1 associated chemokine expression and Th1 trafficking to inflamed tissues and limits pathogen clearance. PLoS ONE 8, e71949 (2013).
51. Wagner, F., Fischer, N., Lersch, C., Hart, R. & Dancygier, H. Interleukin 4 inhibits the interleukin 2 induced production of its functional antagonist, interferon. Immunol. Lett. 21, 237-241 (1989).
52. Van Dyken, S. J. & Locksley, R. M. Interleukin 4- and interleukin 13 mediated alternatively activated macrophages: roles in homeostasis and disease. Annu. Rev. Immunol. 31, 317-343 (2013).
53. Hershey, G. K. IL 13 receptors and signaling pathways: an evolving web. J. Allergy Clin. Immunol. 111, 677-690 (2003).
54. Akaiwa, M. et al. Localization of human interleukin 13 receptor in non-haematopoietic cells. Cytokine 13, 75-84 (2001).
55. McKenzie, G. J., Fallon, P. G., Emson, C. L., Grencis, R. K. & McKenzie, A. N. Simultaneous disruption of interleukin (IL)-4 and IL 13 defines individual roles in T helper cell type 2 mediated responses. J. Exp. Med. 189, 1565-1572 (1999).
56. LaPorte, S. L. et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin 4/13 system. Cell 132, 259-272 (2008).
57. Laporte, J. C. et al. Direct effects of interleukin 13 on signaling pathways for physiological responses in cultured human airway smooth muscle cells. Am. J. Respir. Crit. Care Med. 164, 141-148 (2001).
58. Chatila, T. A. Interleukin 4 receptor signaling pathways in asthma pathogenesis. Trends Mol. Med. 10, 493-499 (2004).
59. Finkelman, F. D. et al. Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B cell stimulatory factor 1. Proc. Natl Acad. Sci. USA 83, 9675-9678 (1986).
60. Finkelman, F. D. et al. Regulation of murine in vivo IgG and IgE responses by a monoclonal anti IL 4 receptor antibody. Int. Immunol. 3, 599-607 (1991).
61. Grunewald, S. M. et al. An antagonistic IL 4 mutant prevents type I allergy in the mouse: inhibition of the IL 4/IL 13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo. J. Immunol. 160, 4004-4009 (1998).
62. McKenzie, G. J. et al. Impaired development of Th2 cells in IL 13 deficient mice. Immunity 9, 423-432 (1998).
63. Mohrs, M. et al. Differences between IL 4- and IL 4 receptor α-deficient mice in chronic leishmaniasis reveal a protective role for IL 13 receptor signaling. J. Immunol. 162, 7302-7308 (1999).
64. Ogata, H. et al. Regulation of interleukin 13 receptor constituents on mature human B lymphocytes. J. Biol. Chem. 273, 9864-9871 (1998).
65. Kouro, T. & Takatsu, K. IL 5- and eosinophil-mediated inflammation: from discovery to therapy. Int. Immunol. 21, 1303-1309 (2009).
66. Yamada, T. et al. IL 3, IL 5, granulocyte-macrophage colony- stimulating factor receptor α subunit, and common β-subunit expression by peripheral leukocytes and blood dendritic cells. J. Allergy Clin. Immunol. 101, 677-682 (1998).
67. Foster, P. S., Hogan, S. P., Ramsay, A. J., Matthaei, K. I. & Young, I. G. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J. Exp. Med. 183, 195-201 (1996).
68. Busse, W. W., Ring, J., Huss-Marp, J. & Kahn, J. E. A review of treatment with mepolizumab, an anti IL 5 mAb, in hypereosinophilic syndromes and asthma. J. Allergy Clin. Immunol. 125, 803-813 (2010).
69. Moqbel, R. & Odemuyiwa, S. O. Allergy, asthma, and inflammation: which inflammatory cell type is more important? Allergy Asthma Clin. Immunol. 4, 150-156 (2008).
70. Webb, D. C. et al. Integrated signals between IL 13, IL 4, and IL 5 regulate airways hyperreactivity. J. Immunol. 165, 108-113 (2000).
71. Rosenberg, H. F., Phipps, S. & Foster, P. S. Eosinophil trafficking in allergy and asthma. J. Allergy Clin. Immunol. 119, 1303-1310 (2007).
72. Gavett, S. H. et al. Interleukin 4 receptor blockade prevents airway responses induced by antigen challenge in mice. Am. J. Physiol. 272, L253-L261 (1997).
73. Brusselle, G. G. et al. Attenuation of allergic airway inflammation in IL 4 deficient mice. Clin. Exp. Allergy 24, 73-80 (1994).
74. Walter, D. M. et al. Critical role for IL 13 in the development of allergen-induced airway hyperreactivity. J. Immunol. 167, 4668-4675 (2001).
75. Cockcroft, D. W. & Davis, B. E. Mechanisms of airway hyperresponsiveness. J. Allergy Clin. Immunol. 118, 551-559 (2006).
76. Katial, R. K. & Covar, R. A. Bronchoprovocation testing in asthma. Immunol. Allergy Clin. North Am. 32, 413-431 (2012).
77. Grunig, G. et al. Requirement for IL 13 independently of IL 4 in experimental asthma. Science 282, 2261-2263 (1998).
78. Wills-Karp, M. et al. Interleukin 13: central mediator of allergic asthma. Science 282, 2258-2261 (1998).
79. Komai, M. et al. Role of Th2 responses in the development of allergen-induced airway remodelling in a murine model of allergic asthma. Br. J. Pharmacol. 138, 912-920 (2003).
80. Zhu, Z. et al. Pulmonary expression of interleukin 13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103, 779-788 (1999).
81. Chu, H. W. et al. Collagen deposition in large airways may not differentiate severe asthma from milder forms of the disease. Am. J. Respir. Crit. Care Med. 158, 1936-1944 (1998).
82. Kanoh, S., Tanabe, T. & Rubin, B. K. IL 13 induced MUC5AC production and goblet cell differentiation is steroid resistant in human airway cells. Clin. Exp. Allergy 41, 1747-1756 (2011).
83. Kurowska-Stolarska, M. et al. IL 33 induces antigen-specific IL 5+ T cells and promotes allergic-induced airway inflammation independent of IL 4. J. Immunol. 181, 4780-4790 (2008).
84. Li, Y. L. et al. Thymic stromal lymphopoietin promotes lung inflammation through activation of dendritic cells. J. Asthma 47, 117-123 (2010).
85. Lee, G. R. & Flavell, R. A. Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma. Int. Immunol. 16, 1155-1160 (2004).
86. Zheng, T. et al. Transgenic expression of interleukin 13 in the skin induces a pruritic dermatitis and skin remodeling. J. Invest. Dermatol. 129, 742-751 (2009).
87. Rankin, J. A. et al. Phenotypic and physiologic characterization of transgenic mice expressing interleukin 4 in the lung: lymphocytic and eosinophilic inflammation without airway hyperreactivity. Proc. Natl Acad. Sci. USA 93, 7821-7825 (1996).
88. Chan, L. S., Robinson, N. & Xu, L. Expression of interleukin 4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J. Invest. Dermatol. 117, 977-983 (2001).
89. Buttner, C., Lun, A., Splettstoesser, T., Kunkel, G. & Renz, H. Monoclonal anti-interleukin 5 treatment suppresses eosinophil but not T cell functions. Eur. Respir. J. 21, 799-803 (2003).
90. Flood-Page, P. et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med. 176, 1062-1071 (2007).
91. Leckie, M. J. et al. Effects of an interleukin 5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356, 2144-2148 (2000).
92. Oldhoff, J. M. et al. No effect of anti-interleukin 5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Int. Arch. Allergy Immunol. 141, 290-294 (2006).
93. Barnes, P. J. Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine Growth Factor Rev. 14, 511-522 (2003).
94. Oldhoff, J. M. et al. Anti IL 5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 60, 693-696 (2005).
95. Borish, L. C. et al. Efficacy of soluble IL 4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 107, 963-970 (2001).
96. Borish, L. C. et al. Interleukin 4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 160, 1816-1823 (1999).
97. Gauvreau, G. M. et al. The effects of IL 13 blockade on allergen-induced airway responses in mild atopic asthma. Am. J. Respir. Crit. Care Med. 183, 1007-1014 (2010).
98. Maes, T., Joos, G. F. & Brusselle, G. G. Targeting interleukin 4 in asthma: lost in translation? Am. J. Respir. Cell. Mol. Biol. 47, 261-270 (2012).
99. Oh, C. K., Geba, G. P. & Molfino, N. Investigational therapeutics targeting the IL 4/IL 13/STAT 6 pathway for the treatment of asthma. Eur. Respir. Rev. 19, 46-54 (2010).
100. Economides, A. N. et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. 9, 47-52 (2003).
101. Wenzel, S., Wilbraham, D., Fuller, R., Getz, E. B. & Longphre, M. Effect of an interleukin 4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370, 1422-1431 (2007).
102. Groves, R. W., Wilbraham, D., Fuller, R. & Longphre, M. Inhibition of IL 4 and IL 13 with an IL 4 mutein (Aeroderm) protects against flares in atopic eczema. J. Invest. Dermatol. 127, S54 (2007).
103. Corren, J. et al. A randomized, controlled, phase 2 study of AMG 317, an IL 4Rα antagonist, in patients with asthma. Am. J. Respir. Crit. Care Med. 181, 788-796 (2010).
104. Kakkar, T. et al. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Pharm. Res. 28, 2530-2542 (2011).
105. Wenzel, S. E. Asthma: defining of the persistent adult phenotypes. Lancet 368, 804-813 (2006).
106. Haldar, P. et al. Cluster analysis and clinical asthma phenotypes. Am. J. Respir. Crit. Care Med. 178, 218-224 (2008).
107. Moore, W. C. et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am. J. Respir. Crit. Care Med. 181, 315-323 (2010).
108. Haldar, P. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360, 973-984 (2009).
109. Fahy, J. V. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc. Am. Thorac Soc. 6, 256-259 (2009).
110. Takayama, G. et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL 4 and IL 13 signals. J. Allergy Clin. Immunol. 118, 98-104 (2006).
111. Woodruff, P. G. et al. T helper type 2 driven inflammation defines major subphenotypes of asthma. Am. J. Respir. Crit. Care Med. 180, 388-395 (2009).
112. Nair, P. et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 360, 985-993 (2009).
113. Pavord, I. D. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380, 651-659 (2012).
114. Ortega, H. G. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371, 1198-1207 (2014).
115. Ultsch, M. et al. Structural basis of signaling blockade by anti IL 13 antibody lebrikizumab. J. Mol. Biol. 425, 1330-1339 (2013).
116. Scheerens, H. et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin. Exp. Allergy 44, 38-46 (2014).
117. Corren, J. et al. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 365, 1088-1098 (2011).
118. Noonan, M. et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J. Allergy Clin. Immunol. 132, 567-574. e12 (2013).
119. Wenzel, S. E. et al. Inhaled pitrakinra, an IL 4/IL 13 antagonist, reduced exacerbations in patients with eosinophilic asthma. Eur. Respir. J. 36 (Suppl. 54), 713s (2010).
120. Juniper, E. F., Svensson, K., Mork, A. C. & Stahl, E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir. Med. 99, 553-558 (2005).
121. Wenzel, S. et al. Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl. J. Med. 368, 2455-2466 (2013).
122. Wenzel, S. et al. Dupilumab improves lung function and reduces severe exacerbations in uncontrolled asthmatics with baseline eosinophil levels above and below 300 cells/?l. Am. J. Respir. Crit. Care Med. 191, A3632 (2015).
123. Chase, E. P. & Armstrong, A. W. Advances in management of atopic dermatitis: new therapies and novel uses of existing treatments. Semin. Cutan Med. Surg. 31, 17-24 (2012).
124. Ong, P. Y. Emerging drugs for atopic dermatitis. Expert Opin. Emerg. Drugs 14, 165-179 (2009).
125. Radin, A., R. H., Papino-Wood, P., Chaudhry, U. & Hamilton, J. D. First in human study of REGN668/ SAR231893 (IL 4Rα mAb): safety, tolerability and biomarker results of a randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers. J. Allergy Clin. Immunol. 131, SAB158 (2013).
126. Beck, L. A. et al. Dupilumab treatment in adults with moderate-to severe atopic dermatitis. N. Engl. J. Med. 371, 130-139 (2014).
127. Kam, J. C., Szefler, S. J., Surs, W., Sher, E. R. & Leung, D. Y. Combination IL 2 and IL 4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J. Immunol. 151, 3460-3466 (1993).
128. Leung, D. Y. et al. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor β. J. Exp. Med. 186, 1567-1574 (1997).
129. Hamilton, J. D. et al. Dupilumab improves the molecular signature in skin of patients with moderate-to severe atopic dermatitis. J. Allergy Clin. Immunol. 134, 1293-1300 (2014).
130. Fokkens, W. J. et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 50, 1-12 (2012).
131. Van Zele, T. et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J. Allergy Clin. Immunol. 125, 1069-1076. e4 (2010).
132. Pinto, J. M. et al. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 48, 318-324 (2010).
133. Gevaert, P. et al. Nasal IL 5 levels determine the response to anti IL 5 treatment in patients with nasal polyps. J. Allergy Clin. Immunol. 118, 1133-1141 (2006).
134. Bachert, C. et al. Dupilumab in chronic sinusitis with nasal polyposis, with and without asthma. EAACI Online Library [online], http://eaaci. multilearning. com/ eaaci/2015/barcelona/104799/claus. bachert. dupilumab. in. chronic. sinusitis. with. nasal. polyposis. with. and. html?f=m3 (2015).
135. Stalder, J. F. & Taeb, A. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology 186, 23-31 (1993).
136. Haeck, I. M. et al. Moderate correlation between quality of life and disease activity in adult patients with atopic dermatitis. J. Eur. Acad. Dermatol. Venereol. 26, 236-241 (2012).
137. Hanifin, J. M. et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp. Dermatol. 10, 11-18 (2001).
138. Barbier, N. et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br. J. Dermatol. 150, 96-102 (2004).
139. Phan, N. Q. et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm. Venereol. 92, 502-507 (2012).
140. Berger, W. E. et al. Efficacy and safety evaluation of ciclesonide in subjects with mild to moderate asthma not currently using inhaled corticosteroids. Allergy Asthma Proc. 30, 304-314 (2009).
141. Noonan, M. J. et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Eur. Respir. J. 11, 1232-1239 (1998).
142. Cockcroft, D. W. Direct challenge tests: airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 138, 18S-24S (2010).
143. Juniper, E. F., Bousquet, J., Abetz, L. & Bateman, E. D. Identifying well-controlled and not well-controlled asthma using the Asthma Control Questionnaire. Respir. Med. 100, 616-621 (2006).
144. Juniper, E. F., OByrne, P. M., Guyatt, G. H., Ferrie, P. J. & King, D. R. Development and validation of a questionnaire to measure asthma control. Eur. Respir. J. 14, 902-907 (1999).
145. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (Global Initiative for Asthma, 2015).
146. Diamant, Z., Boot, D., Kamerling, I. & Bjermer, L. Methods used in clinical development of novel anti-asthma therapies. Respir. Med. 102, 332-338 (2008).
147. Kaiser, J. Medical Officers Efficacy Review, Genentech, Omalizumab BLA STN 103976/0. US Food and Drug Administration [online], http://www. fda. gov/ downloads/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ ApprovalApplications/TherapeuticBiologicApplications/ ucm113459. pdf (2003).
148. Gevaert, P. et al. Mepolizumab, a humanized anti IL 5 mAb, as a treatment option for severe nasal polyposis. J. Allergy Clin. Immunol. 128, 989-995. e8 (2011).
149. Groves, R., Wilbrahams, D., Fuller, R. & Longphre, M. Inhibition of IL 4 and IL 13 with an IL 4 mutein (Aeroderm) protects against flares in atopic eczema. J. Invest. Dermatol. 127 (Suppl. 1s), S54 (2007).